greeksoup/ stock research
Stock research / United States / ILMN · Laboratory Analytical Instruments · Nasdaq

Illumina, Inc. (ILMN)

Illumina makes the instruments and consumables used to read DNA. Its tools are used to study genetic variation and function, which the filing frames as advancing disease research, drug development and the creation of molecular diagnostic tests. Most of what it sells is sequencing and array instruments plus the consumables that run on them, meaning reagents, flow cells and library preparation, and it also performs services. The split matters: instruments were 11 percent of what the company sold in 2025, against 12 percent in 2024 and 16 percent in 2023, while consumables were 74 percent, up from 72 and 68 percent, and services and other 15 percent. Arrays specifically were 8 percent of the 2025 total, against 9 percent in each of the two prior years. The global workforce at 28 December 2025 was approximately 8,600 full-time employees, 50 part-time and 1,430 contingent workers, roughly 4,740 of them in the Americas.

Illumina, Inc.

Illumina makes the instruments and consumables used to read DNA. Its tools are used to study genetic variation and function, which the filing frames as advancing disease research, drug development and the creation of molecular diagnostic tests. Most of what it sells is sequencing and array instruments plus the consumables that run on them, meaning reagents, flow cells and library preparation, and it also performs services. The split matters: instruments were 11 percent of what the company sold in 2025, against 12 percent in 2024 and 16 percent in 2023, while consumables were 74 percent, up from 72 and 68 percent, and services and other 15 percent. Arrays specifically were 8 percent of the 2025 total, against 9 percent in each of the two prior years. The global workforce at 28 December 2025 was approximately 8,600 full-time employees, 50 part-time and 1,430 contingent workers, roughly 4,740 of them in the Americas.

Sequencing

DNA sequencing determines the order of the nucleotide bases in a sample. Customers use the platforms for whole-genome, de novo, exome and RNA sequencing and for targeted resequencing of particular genes. The chemistry is proprietary reversible terminator-based sequencing, which the company calls sequencing by synthesis, tracking labelled nucleotides as the DNA chain is copied in a massively parallel fashion; XLEAP-SBS is the current version, and the filing states it allows more than 20,000 human genomes per year per instrument. The platforms generate between 500 megabases and 16.0 terabases of genomic data in a single run depending on the instrument and application, at different price points per gigabase. The first sequencing system launched in 2007. The NovaSeq X Plus, launched in 2023, is the production-scale system and the filing says it can sequence a human genome for as little as $200. The MiSeq i100 series, launched in 2024, is the benchtop system, with room-temperature reagents.

Arrays

Arrays handle SNP genotyping, copy number variation analysis and methylation analysis, detecting millions of known genetic or epigenetic markers on a single array, and are used in agrigenomics, cytogenetics, pharmacogenomics, oncology, disease risk screening and large-scale research. BeadArray technology combines microscopic beads with a substrate so many assays run at once, and the substrate size, shape and format and the bead types vary by market. The iScan System and the NextSeq 550 System image the arrays.

Informatics

Software sits around the instruments across sample preparation, instrument control and post-run analysis. The BaseSpace Informatics Suite integrates directly with the sequencers so customers can manage samples and runs, process raw genomic data and share it. The DRAGEN Bio-IT Platform handles secondary analysis across whole genomes, whole exomes, germline and somatic datasets and RNA sequencing. Illumina Connected Analytics is a cloud-based platform for large volumes of multi-omic data, and Illumina Connected Multiomics extends it across genomics, transcriptomics, proteomics and other data types. Two products are for research use only and not for diagnostic procedures: Emedgene, an AI-driven genomic interpretation platform, and Illumina Connected Insights, which aggregates curated knowledge sources, public databases and variant annotations into one research environment.

Who buys it

The core market has historically been life sciences research: laboratories at universities, research centres and government institutions, plus biotechnology and pharmaceutical companies, working across targeted, exome and whole-genome sequencing, genetic variation, gene expression, epigenetics and metagenomics. Applied markets include consumer genomics, where customers provide personalised genetic data to individuals, and agrigenomics, where marker-based applications accelerate breeding of crops and livestock. The clinical side runs through oncology, genetic health and reproductive health. In oncology, customers identify genetic predisposition, find molecular changes in a tumour that targeted therapies may address, and detect traces of cancer in blood signalling an undetected tumour or a recurrence. In reproductive health the focus is noninvasive prenatal testing, identifying fetal chromosomal abnormalities from cell-free DNA in maternal blood.

Selling and making

Products are marketed and distributed directly in North America, Europe, Latin America and the Asia-Pacific region, and through life-science distributors in certain markets within Europe, Asia-Pacific, Latin America, the Middle East and Africa. The company manufactures the platforms and the reagent kits itself, and states that it increased manufacturing capability and capacity in 2025 and expects to do so again in 2026. Processes continue to be automated to handle rising product complexity and volume, and the key manufacturing and distribution facilities are certified to ISO 13485.

From Illumina's annual report on Form 10-K for the year ended 28 December 2025. The filing carries no Item 1 or Item 7 heading in its body, using a cross-reference index instead, so nothing here was located by section name. The filing

Compare with another name What $10,000 in Illumina became

Latest results

Latest quarterQ3 FY2026ended 27 September 2026 · 10-Q filed 30 October 2026
Revenue
$1.1 billion
+4.2% on the year · -2.6% on the quarter
Q4 FY2024Q3 FY2026
Net income
$220 million
+46.7% on the year · +6.3% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$1.43
+45.9% on the year · +5.9% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 28 December 2025 · 10-K filed 12 February 2026
Revenue
$4.3 billion
-0.7% on the year
FY2018FY2025
Net income
$850 million
FY2018FY2025
Diluted EPS
$5.45
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsIllumina (ILMN) reported revenue of $4.3 billion for fiscal 2025, the year ended 28 December 2025, down 0.7% on the year before. Net income was $850 million and diluted earnings per share $5.45. Revenue was $4.4 billion in fiscal 2024, $4.5 billion in fiscal 2023, $4.6 billion in fiscal 2022 and $4.5 billion in fiscal 2021. Net income in the same years was a loss of $1.2 billion, a loss of $1.2 billion, a loss of $4.4 billion and $762 million. Over the twelve months to 27 September 2026, Illumina reported revenue of $4.5 billion and net income of $895 million. Revenue grew 6.0% a year, compounded, over the five years to fiscal 2025. Illumina had 151 million shares outstanding at the latest filed count. At 27 September 2026 it carried $1.8 billion of debt and $1.3 billion of cash. At the close of 6 November 2026 the market cap of Illumina was $32.2 billion, 36.7 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE28.5%
ROCE19.5%
Operating margin21.2%
Net margin19.7%
FCF margin23.3%
Interest cover9.8x
Debt to equity0.57x
Cash conversion1.37x
Share count, last 12 months-1.0%
Sales CAGR, 3 years-1.8%
Profit CAGR, 3 yearsn/a
EPS, TTM$5.81

At the close of 6 November 2026

Price$213.05
Market cap$32.2 billion
Stock P/E36.7x
Price to book10.2x
EV / EBITDA26.4x
Dividend yieldn/a
Market cap / sales7.1x
52-week high$293.84
52-week low$114.44
Price, 1 year75.9%
Price CAGR, 3 years24.0%
Price CAGR, 5 years-11.7%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowings Illumina, Inc. reports under its own heading, which is the only one it files; lease liabilities are separate lines. Nothing here is a valuation or a view.
ILMNgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023 †Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue1,1991,2231,1621,1151,0841,0871,1761,1191,1221,0761,1121,0801,1041,0411,0591,0841,1591,0911,1591,129
Cost of revenue381408395398411432444435449409391335376358364351400370389299
Gross profit818815767717673655732684673667721745728683695733759721770830
Gross margin68%67%66%64%62%60%62%61%60%62%65%69%66%66%66%68%65%66%66%74%
R&D350323327325346341358315340339325253252252247229239240252244
SG&A426308410146433378462303481439147239267267234277308272273281
Operating income42.0184-579-3,657-127-64.0-88.0-754-163-111-1,637741174164214227202209245305
Operating margin4%15%-50%-328%-12%-6%-7%-67%-15%-10%-147%69%16%16%20%21%17%19%21%27%
Interest expense12.06.06.06.08.020.019.019.019.018.020.036.026.025.025.025.026.024.024.024.0
Pre-tax income88.0140-637-3,672-167-78.0-89.0-782-168-109-1,976720186182306220378157260264
Tax rate-28%39%n/an/an/an/an/an/an/an/an/a2%0%28%23%32%12%15%20%17%
Net income11386.0-535-3,816-1393.0-234-754-176-126-1,988705186131235150334134207220
Net margin9%7%-46%-342%-13%0%-20%-67%-16%-12%-179%65%17%13%22%14%29%12%18%19%
Diluted EPS$0.70$0.55-$3.40-$24.26-$0.89$0.02-$1.48-$4.77-$1.11-$0.79-$12.48$4.42$1.17$0.82$1.49$0.98$2.16$0.87$1.35$1.43
Operating cash flow282172125-52.014710.010513922477.080.0316364240234284321289201419
Capital expenditure70.061.071.066.088.052.047.045.051.036.031.032.029.032.030.031.055.038.040.040.0
Free cash flow21211154.0-11859.0-42.058.094.017341.049.0284335208204253266251161379
Buybacksn/an/an/an/an/an/an/an/an/a0.00.099.017.020037013042.02421289.0
Shares outstanding157m157m157m157m158m158m158m159m159m159m159m159m159m158m154m153m153m151m151m151m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2008FY2009FY2010 †FY2011 †FY2012FY2013FY2014FY2015 †FY2016 †FY2017FY2018FY2019 †FY2020FY2021FY2022FY2023FY2024FY2025TTM
Revenue5736669031,0561,1491,4211,8612,2202,3982,7523,3333,5433,2394,5264,5844,5044,3724,3434,538
Cost of revenue2202123013463755095646707329261,0331,0761,0361,3721,6121,7601,5111,4731,458
Gross profit3534546027097749121,2981,5491,6661,8262,3002,4672,2033,1542,9722,7442,8612,8703,080
Gross margin61.6%68.1%66.6%67.2%67.4%64.2%69.7%69.8%69.5%66.4%69.0%69.6%68.0%69.7%64.8%60.9%65.4%66.1%67.9%
Research and development100.01411781972312773884025045466236476821,1851,3211,3541,169967975
Selling, general and administrative1481762202622863814665165836747948359412,0921,2971,6121,0921,0861,134
Operating income80.5126212199201134515613587606883985580-123-4,179-1,069-833807961
Operating margin14.0%18.8%23.4%18.9%17.5%9.4%27.7%27.6%24.5%22.0%26.5%27.8%17.9%-2.7%-91.2%-23.7%-19.1%18.6%21.2%
Interest expense22.223.724.634.837.839.741.743.033.037.057.052.049.061.026.077.010010198.0
Pre-tax income72.71141851332231594495835611,0438941,118856884-4,336-1,117-1,1791,0861,059
Income tax33.341.860.546.471.434.095.412513336511212820012268.044.044.0236164
Effective tax rate45.8%36.7%32.6%34.9%32.1%21.3%21.3%21.4%23.7%35.0%12.5%11.4%23.4%13.8%n/an/an/a21.7%15.5%
Net income39.472.312586.61511253534624637268261,002656762-4,404-1,161-1,223850895
Net margin6.9%10.8%13.8%8.2%13.2%8.8%19.0%20.8%19.3%26.4%24.8%28.3%20.3%16.8%-96.1%-25.8%-28.0%19.6%19.7%
Diluted EPS$0.30$0.53$0.87$0.62$1.13$0.90$2.37$3.10$3.07$4.92$5.56$6.74$4.45$5.04-$28.00-$7.34-$7.69$5.45$5.81
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2014 to FY2025

FY2014FY2016FY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025Share
of the parts, latest year
Core Illumina1,8612,2202,4282,7543,3343,5433,239n/an/an/an/a4,343100.0%
GRAILn/an/an/an/an/an/an/an/an/an/an/a0.0n/a
Helix0.00.0n/a6.010.01.00.0n/an/an/an/an/an/a
Microarrayn/an/an/an/an/an/an/a417413392379n/an/a
Sequencingn/an/an/an/an/an/an/a4,1094,1714,1123,993n/an/a
Eliminationsn/an/a-30.0n/an/an/an/an/an/an/an/an/an/a
Core Illumina FY2014 to FY2025Sequencing FY2022 to FY2024Microarray FY2022 to FY2024Helix FY2017 to FY2019
2,220FY20162,760FY20173,544FY20194,526FY20224,504FY20234,343FY2025

$ million; hover a block for its figure and share; the figure over a bar is its parts, before the lines named below; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in. Eliminations is the company's own eliminations and corporate items, which take the parts to revenue: shown as filed, with no share and no block in the chart.

Profit by segment FY2014 to FY2021

The operating profit each segment reports. Costs Illumina does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.

FY2014FY2016FY2017FY2017FY2018FY2019FY2021Margin
FY2021
Core Illumina5156216846969701,00858017.9%
GRAILn/an/an/an/an/a0.00.0n/a
Helix0.0-8.0-81.0-92.0-90.0-24.0n/an/a
Core IlluminaHelix FY2016 to FY2019
515FY2014613FY2016603FY2017604FY2017880FY2018984FY2019580FY2021

$ million; the figure over a bar is all the segments together; a year a segment lost money, it hangs below the line. Hover a block for its profit, sales and margin.

FY2021Share of salesShare of profit
Core Illumina100%100%
GRAIL0%a loss

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.

Revenue by product or service FY2017 to FY2025

FY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025Share
of the parts, latest year
Consumables1,5431,7712,1772,3922,3043,2173,2253,0833,1553,22774.3%
Servicen/an/an/an/an/a55863171771663414.6%
Instruments46951857253743175172870450148211.1%
Other product20n/an/an/an/an/an/an/an/an/an/a
Service and other revenue366463584614504n/an/an/an/an/an/a
ConsumablesService FY2022 to FY2025InstrumentsService and other revenue FY2017 to FY2021Other product FY2017
2,752FY20173,543FY20194,526FY20224,504FY20234,343FY2025

$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Revenue by region FY2010 to FY2025

FY2010FY2011FY2012FY2012FY2013FY2014FY2016FY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025Share
of the parts, latest year
Americasn/an/an/an/an/an/an/an/an/a1,8641,9701,7442,3582,4792,5212,4412,40655.4%
Europen/an/an/an/a355467527553632n/an/an/a1,1491,0891,1401,1851,26429.1%
Asia-Pacific, Middle East and African/an/an/an/an/an/an/an/an/an/an/an/a5175444594384309.9%
Chinan/an/an/an/an/an/an/an/an/a3653723425024723843082435.6%
Asia-Pacific96.4143197232276343380456222253268267n/an/an/an/an/an/a
Europe, Middle East, and African/an/an/an/an/an/an/an/an/a851933886n/an/an/an/an/an/a
European countriesn/an/a278291n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Greater Chinan/an/an/an/an/an/an/an/a292n/an/an/an/an/an/an/an/an/a
Other European countries141163n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Other markets25.936.751.856.275.410110695.095.0n/an/an/an/an/an/an/an/an/a
United Kingdom55.960.5n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
United States3474995295687159511,2071,2941,511n/an/an/an/an/an/an/an/an/a
Americas FY2018 to FY2025Europe FY2013 to FY2025Asia-Pacific, Middle East and Africa FY2022 to FY2025China FY2018 to FY2025Asia-Pacific FY2010 to FY2021Europe, Middle East, and Africa FY2018 to FY2021United States FY2010 to FY2017Other markets FY2010 to FY2017Greater China FY2017European countries FY2012 to FY2012Other European countries FY2010 to FY2011United Kingdom FY2010 to FY2011
903FY20111,421FY20132,398FY20173,543FY20194,584FY20234,343FY2025

$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2008FY2009FY2010 †FY2011 †FY2012FY2013FY2014FY2015 †FY2016 †FY2017FY2018FY2019 †FY2020FY2021FY2022FY2023FY2024FY2025TTM
Operating cash flow87.91722733582923865017867798751,1421,0511,0805453924788371,0791,230
Capital expenditure59.752.749.877.868.879.2106143260310296209189208286195128148173
Free cash flow28.21202232802233073956435195658468428913371062837099311,057
Free cash flow margin4.9%17.9%24.7%26.6%19.4%21.6%21.2%29.0%21.6%20.5%25.4%23.8%27.5%7.4%2.3%6.3%16.2%21.4%23.3%
Cash from investing-277-257-285-401-150-69.6-407-107-515-214-1,813745-554-1,069-591-231-178-55.0-330
Cash from financing338-98.911697.0-10.8-38.7-167-545-296-176594-897-766-51.01,000-1,210-570-744-665
Depreciation and amortisation27.731.242.069.265.397.9113127141156179188187251394432354270277
Share-based compensation47.760.871.692.194.3106153133129164193194194754366380370275270
Buybacks70.817544.057082.550.02372742492512013247360.00.00.0116742421
Diluted shares, weighted134m137m143m139m134m140m149m149m148m148m149m149m148m151m157m158m159m156m154m
Shares outstanding at period endn/an/a127m122m124m128m144m147m146m147m147m147m146m157m158m159m159m153m151m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2008FY2009FY2010 †FY2011 †FY2012FY2013FY2014FY2015 †FY2016 †FY2017FY2018FY2019 †FY2020FY2021FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity7998641,1981,0751,3191,5331,4631,8492,1972,7493,7584,6134,69410,7406,5995,7452,3732,7233,145
Non-controlling interestn/an/an/an/an/an/an/an/a73.0n/a87.00.0n/an/an/an/an/an/an/a
Redeemable equityn/an/an/an/an/a0.30.033.043.922061.00.00.0n/an/an/an/an/an/a
Debtn/an/a3128078428691,2911,0911,0581,1921,9971,1411,1841,6952,7351,4891,9891,9891,789
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/a695671774744687554486439
Other liabilitiesn/a5663303134056175867169081,0961,0568671,0362,0082,1742,1901,3871,4461,439
Total liabilities and equityn/a1,4301,8392,1962,5663,0193,3403,6884,2815,2576,9597,3167,58515,21712,25210,1116,3036,6446,812
Owned
Fixed assetsn/a1171301431662032653437139311,0758899221,0241,0911,007815759731
Goodwilln/a2132783223697237257537767718318978977,1133,2392,5451,1131,1131,284
Intangible assetsn/a43.891.51061303313142742431751851451423,2503,2852,993295210391
Investmentsn/a5496458879164547026178249202,3681,3721,66210726.06.093.021548.0
Cash and equivalents3271452493034347126367697351,2251,1442,0421,8101,2322,0111,0481,1271,4181,289
Receivablesn/a158166174215239289386381411514573487648671734735854738
Inventoryn/a92.8142129159154191271300333386359372431568587547564667
Other assetsn/a1111371321762032162763084914561,0391,2931,4121,3611,1911,5781,5111,664
Total assetsn/a1,4301,8392,1962,5663,0193,3403,6884,2815,2576,9597,3167,58515,21712,25210,1116,3036,6446,812
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded6.9%6.0%-1.8%5.8%
Profit growth, compounded6.3%5.3%n/a27.5%
Return on equity, average0.5%-20.0%-13.5%31.2%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Illumina's revenue in fiscal 2025?

Illumina (ILMN) reported revenue of $4.3 billion for fiscal 2025, the year ended 28 December 2025, down 0.7% on the year before.

How much did Illumina earn in fiscal 2025?

Net income was $850 million for fiscal 2025, and diluted earnings per share $5.45.

What is Illumina's P/E ratio?

At the close of 6 November 2026, Illumina traded at 36.7 times its earnings over the twelve months to 27 September 2026.

What is Illumina's market cap?

The market cap of Illumina was $32.2 billion at the close of 6 November 2026.

How much debt does Illumina have?

At 27 September 2026 Illumina carried $1.8 billion of debt and $1.3 billion of cash.

Peers: Measuring and Control Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Agilent Technologies, Inc. A$49.3 billion34.4019.6%22.2%8.6%0.540.6%
Waters Corp. WAT$45.0 billion114.141.1%7.1%52.5%0.33n/a
Mettler Toledo International Inc. MTD$37.3 billion37.301,202.8%n/a6.5%26.06n/a
Illumina, Inc. ILMN$32.2 billion36.6728.5%21.2%5.8%0.57n/a
Revvity, Inc. RVTY$17.3 billion73.893.3%12.3%4.1%0.450.2%
Avantor, Inc. AVTR$10.5 billion30.935.8%7.3%0.9%0.63n/a
Bio-Rad Laboratories, Inc. BIO$10.3 billion10.0613.5%-2.4%1.4%0.16n/a
Bruker Corp. BRKR$9.4 billionn/a-5.4%-2.0%2.2%0.74n/a
10x Genomics, Inc. TXG$7.8 billionn/a-8.0%-11.7%-3.6%0.00n/a
Alamar Biosciences, Inc. ALMR$1.9 billionn/a-18.1%-42.1%n/a0.00n/a
Cytek Biosciences, Inc. CTKB$765 millionn/a-25.3%-21.1%5.5%0.00n/a
Pacific Biosciences of California, Inc. PACB$703 millionn/an/a-81.3%4.4%n/a0.0%
All 49 in Measuring and Control Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Thermo Fisher Scientific Inc. TMO$257.5 billion36.6512.9%17.9%8.3%0.760.3%
KLA Corp. KLAC$180.5 billion34.6280.6%n/a15.8%0.880.6%
Danaher Corp. DHR$162.0 billion37.698.1%20.4%5.5%0.490.6%
Trane Technologies plc TT$88.0 billion28.3834.6%17.9%10.3%0.461.0%
AMETEK Inc. AME$52.4 billion32.2513.9%26.0%14.3%0.570.6%
Agilent Technologies, Inc. A$49.3 billion34.4019.6%22.2%8.6%0.540.6%
Roper Technologies Inc. ROP$47.2 billion18.8113.5%28.0%9.2%0.510.8%
Keysight Technologies, Inc. KEYS$46.3 billion37.3319.2%20.3%25.5%0.38n/a
Waters Corp. WAT$45.0 billion114.141.1%7.1%52.5%0.33n/a
Rockwell Automation, Inc. ROK$41.7 billion35.2134.4%22.7%11.3%0.931.5%
Coherent Corp. COHR$38.0 billion40.018.5%12.5%30.8%0.35n/a
Mettler Toledo International Inc. MTD$37.3 billion37.301,202.8%n/a6.5%26.06n/a
Teradyne, Inc. TER$34.1 billion25.0537.2%32.1%74.9%0.000.2%
Illumina, Inc. ILMN$32.2 billion36.6728.5%21.2%5.8%0.57n/a
Veralto Corp. VLTO$28.5 billion28.9831.0%21.8%6.4%0.900.4%
Fortive Corp. FTV$19.5 billion31.1411.0%19.6%7.0%0.590.4%
Revvity, Inc. RVTY$17.3 billion73.893.3%12.3%4.1%0.450.2%
MKS Inc. MKSI$13.0 billion22.8018.3%18.2%24.6%1.150.5%
Trimble Inc. TRMB$12.4 billionn/a-3.2%16.5%6.9%0.31n/a
Avantor, Inc. AVTR$10.5 billion30.935.8%7.3%0.9%0.63n/a
Bio-Rad Laboratories, Inc. BIO$10.3 billion10.0613.5%-2.4%1.4%0.16n/a
Bruker Corp. BRKR$9.4 billionn/a-5.4%-2.0%2.2%0.74n/a
Onto Innovation Inc. ONTO$8.5 billion65.106.9%12.0%8.1%0.00n/a
Cognex Corp. CGNX$8.0 billion33.3714.1%25.0%15.8%0.000.7%
10x Genomics, Inc. TXG$7.8 billionn/a-8.0%-11.7%-3.6%0.00n/a
Ralliant Corp. RAL$7.5 billionn/a-73.4%-48.3%n/a0.710.3%
Sensata Technologies Holding plc ST$5.7 billion15.7212.0%15.1%4.1%0.781.2%
Vontier Corp. VNT$5.7 billion17.3028.4%19.4%0.3%1.570.2%
Badger Meter Inc. BMI$4.5 billion36.4719.4%18.8%-2.2%0.001.0%
Mirion Technologies, Inc. MIR$4.4 billion149.581.6%6.0%19.6%0.67n/a
Itron, Inc. ITRI$4.3 billion15.9016.5%13.7%-3.6%0.95n/a
Alamar Biosciences, Inc. ALMR$1.9 billionn/a-18.1%-42.1%n/a0.00n/a
Cohu Inc. COHU$1.9 billionn/a-2.9%-2.4%34.0%0.38n/a
Aehr Test Systems AEHR$1.7 billion1,338.881.0%-5.6%26.8%0.00n/a
Allient Inc. ALNT$1.4 billion36.6811.4%9.8%12.6%0.530.2%
Transcat Inc. TRNS$953 millionn/an/an/an/a0.38n/a
Cytek Biosciences, Inc. CTKB$765 millionn/a-25.3%-21.1%5.5%0.00n/a
Mesa Laboratories Inc. MLAB$718 million152.762.5%9.0%3.0%0.760.5%
Pacific Biosciences of California, Inc. PACB$703 millionn/an/a-81.3%4.4%n/a0.0%
Frequency Electronics Inc. FEIM$661 million241.042.2%2.5%6.3%0.00n/a
Senseonics Holdings, Inc. SENS$454 millionn/a-121.1%-223.2%90.6%0.62n/a
908 Devices Inc. MASS$402 millionn/an/an/an/a0.00n/a
Quantum-Si Inc. QSI$291 millionn/a-53.1%-7,474.5%-60.2%0.00n/a
Nautilus Biotechnology, Inc. NAUT$284 millionn/an/an/an/a0.00n/a
Intest Corp. INTT$173 million38.593.4%3.3%16.6%0.05n/a
Hurco Companies Inc. HURC$132 millionn/a-3.4%-2.8%-1.9%n/an/a
Kewaunee Scientific Corp. KEQU$97 million12.1411.0%5.4%5.3%0.25n/a
Seer, Inc. SEER$90 millionn/a-30.1%-498.2%-12.7%0.000.0%
Rapid Micro Biosystems, Inc. RPID$32 millionn/a-288.5%-141.5%16.1%1.08n/a
15 companies share its SEC industry code (Laboratory Analytical Instruments); the rest are the names nearest in size in its wider industry, Measuring and Control Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on ILMN

Dividendsno dividend in its filings for fiscal 2008 onward
Filings25 in twelve months: 17 current reports (8-K), about 7 other events; 5 results of operations; 3 officer or director change; 2 material agreement; 2 new financial obligation
Planned insider sales26 Form 144 notices in twelve months, $678.0 million; latest 3 November 2026
Options tapeput/call 0.7 by open interest at the 6 November 2026 close; the straddle prices a 10.1% move to 20 November 2026
13F holders944 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading125 sales and 1 purchase on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest7.9 million shares short, 2.94 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q27 September 202630 October 2026EDGAR
10-Q28 June 202631 July 2026EDGAR
10-Q29 March 20264 May 2026EDGAR
10-K28 December 202512 February 2026EDGAR
10-Q28 September 202531 October 2025EDGAR
10-Q29 June 20251 August 2025EDGAR
10-Q30 March 20259 May 2025EDGAR
10-K29 December 202412 February 2025EDGAR
10-Q29 September 20246 November 2024EDGAR
10-Q30 June 20247 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.